Search Results - "van Hulsteijn, L"

Refine Results
  1. 1

    Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis by Niemeijer, N.D., Alblas, G., van Hulsteijn, L.T., Dekkers, O.M., Corssmit, E.P.M.

    Published in Clinical endocrinology (Oxford) (01-11-2014)
    “…Summary Background Chemotherapy with cyclophosphamide, vincristine and dacarbazine (CVD) can be used for palliative treatment of malignant pheochromocytoma and…”
    Get full text
    Journal Article
  2. 2

    No difference in phenotype of the main Dutch SDHD founder mutations by van Hulsteijn, L. T., den Dulk, A. C., Hes, F. J., Bayley, J. P., Jansen, J. C., Corssmit, E. P. M.

    Published in Clinical endocrinology (Oxford) (01-12-2013)
    “…Summary Objective SDHD mutations predispose carriers to hereditary paraganglioma syndrome. The objective of this study was to assess the genotype–phenotype…”
    Get full text
    Journal Article
  3. 3

    Avoiding and Nonexpressing: Coping Styles of Patients With Paragangliomas by van Hulsteijn, L. T, Kaptein, A. A, Louisse, A, Smit, J. W. A, Corssmit, E. P. M

    “…Context: Paraganglioma (PGL) patients and succinate dehydrogenase (SDH) gene mutation carriers at risk for PGLs have a decreased quality of life (QoL). QoL may…”
    Get full text
    Journal Article
  4. 4

    European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity by Pasquali, R, Casanueva, F, Haluzik, M, van Hulsteijn, L, Ledoux, S, Monteiro, M P, Salvador, J, Santini, F, Toplak, H, Dekkers, O M

    Published in European journal of endocrinology (01-01-2020)
    “…Obesity is an emerging condition, with a prevalence of ~20%. Although the simple measurement of BMI is likely a simplistic approach to obesity, BMI is easily…”
    Get full text
    Journal Article
  5. 5

    Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis by van Hulsteijn, L T, Pasquali, R, Casanueva, F, Haluzik, M, Ledoux, S, Monteiro, M P, Salvador, J, Santini, F, Toplak, H, Dekkers, O M

    Published in European journal of endocrinology (01-01-2020)
    “…Objective The increasing prevalence of obesity is expected to promote the demand for endocrine testing. To facilitate evidence guided testing, we aimed to…”
    Get full text
    Journal Article
  6. 6

    (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis by van Hulsteijn, L T, Niemeijer, N D, Dekkers, O M, Corssmit, E P M

    Published in Clinical endocrinology (Oxford) (01-04-2014)
    “…(131)I-MIBG therapy can be used for palliative treatment of malignant paraganglioma and phaeochromocytoma. The main objective of this study was to perform a…”
    Get full text
    Journal Article
  7. 7

    131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis by van Hulsteijn, L. T., Niemeijer, N. D., Dekkers, O. M., Corssmit, E. P. M.

    Published in Clinical endocrinology (Oxford) (01-04-2014)
    “…Summary Background 131I‐MIBG therapy can be used for palliative treatment of malignant paraganglioma and phaeochromocytoma. The main objective of this study…”
    Get full text
    Journal Article
  8. 8

    Carotid body tumors are not associated with an increased risk for sleep-disordered breathing by van Hulsteijn, L. T., van Duinen, N., Ninaber, M. K., Romijn, J. A., van Dijk, J. G., van Kralingen, K. W., Havekes, B., Smid, L., Lammers, G. J., Jansen, J. C., Smit, J. W., Thijs, R. D., Corssmit, E. P. M.

    Published in Sleep & breathing (01-03-2014)
    “…Purpose Tumors in the carotid bodies may interfere with their function as peripheral chemoreceptors. An altered control of ventilation may predispose to…”
    Get full text
    Journal Article
  9. 9
  10. 10

    What is the role of general internists in the tertiary or academic setting? by Tanriover, Mine Durusu, Rigby, Shirley, van Hulsteijn, L. Harry, Ferreira, Faustino, Oliveira, Narcisso, Schumm-Draeger, Petra-Maria, Weidanz, Frauke, Kramer, Mark H.H

    Published in European journal of internal medicine (01-01-2015)
    “…Abstract The changing demography of European populations mandates a vital role for internists in caring for patients in each level of healthcare. Internists in…”
    Get full text
    Journal Article
  11. 11

    Quality of life is decreased in patients with paragangliomas by van Hulsteijn, L T, Louisse, A, Havekes, B, Kaptein, A A, Jansen, J C, Hes, F J, Smit, J W A, Corssmit, E P M

    Published in European journal of endocrinology (01-05-2013)
    “…ContextGermline mutations in succinate dehydrogenase (SDH) genes predispose carriers for developing paragangliomas, and studies on their quality of life (QoL)…”
    Get full text
    Journal Article
  12. 12

    Illness perceptions, risk perception and worry in SDH mutation carriers by van Hulsteijn, L. T., Kaptein, A. A., Louisse, A., Biermasz, N. R., Smit, J. W. A., Corssmit, E. P. M.

    Published in Familial cancer (01-03-2014)
    “…Succinate dehydrogenase (SDH) mutation carriers are predisposed for developing paragangliomas. This study aimed to explore illness perceptions, risk perception…”
    Get full text
    Journal Article
  13. 13

    The value of clinical examination in diagnosing pelvic fractures in blunt trauma patients: a brief review by den Boer, T. A. W., Geurts, M., van Hulsteijn, L. T., Mubarak, A., Slingerland, J., Zwart, B., van der Heijden, G. J. M. G., Blokhuis, T. J.

    “…Purpose of the study To evaluate the value of a pelvic X-ray compared to clinical examination in diagnosing pelvic ring fractures, using computed tomography…”
    Get full text
    Journal Article
  14. 14

    131 I‐ MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta‐analysis by van Hulsteijn, L. T., Niemeijer, N. D., Dekkers, O. M., Corssmit, E. P. M.

    Published in Clinical endocrinology (Oxford) (01-04-2014)
    “…Summary Background 131 I‐ MIBG therapy can be used for palliative treatment of malignant paraganglioma and phaeochromocytoma. The main objective of this study…”
    Get full text
    Journal Article
  15. 15

    No difference in phenotype of the main D utch SDHD founder mutations by van Hulsteijn, L. T., den Dulk, A. C., Hes, F. J., Bayley, J. P., Jansen, J. C., Corssmit, E. P. M.

    Published in Clinical endocrinology (Oxford) (01-12-2013)
    “…Summary Objective SDHD mutations predispose carriers to hereditary paraganglioma syndrome. The objective of this study was to assess the genotype–phenotype…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Out of hospital treatment with subcutaneous low molecular weight heparin in patients with acute deep-vein thrombosis: a prospective study in daily practice by Zidane, M, van Hulsteijn, LH, Brenninkmeijer, BJ, Huisman, MV

    Published in Haematologica (Roma) (01-08-2006)
    “…Section of Vascular Medicine, Department of General Internal Medicine and Endocrinology, Room C4-68 Leiden University Medical Center, Leiden, The Netherlands…”
    Get full text
    Journal Article